ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,262.08
1.38%
Dow Jones
44,296.51
0.97%
Gold vs US Dollar
2,715.28
0.00%
Brent Oil
74.65
0.00%
Bitcoin
96,043.22
-1.78%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX

  6. Eupraxia Pharmaceuticals Inc (EPRX) Share Price

EPRX Eupraxia Pharmaceuticals Inc

4.91
0.18 (3.81%)
22 Nov 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Eupraxia Pharmaceuticals Inc TSX:EPRX Toronto Stock Exchange Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.18 3.81 4.91 4.73 4.92 4.89 4.70 4.72 16,571 21:00:01   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -28.22M -1.0344 -4.73 129.04M
 Type  Size  Price  Time  Units 
  100 4.91 21:00:00 CAD
 
Recent News
DateTimeSource
HeadlineMore EPRX News
20/11/202412:00PRNCAEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
20/11/202412:00PRNUSEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
14/11/202422:00PRNCAEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
14/11/202422:00PRNUSEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
13/11/202422:00PRNCAEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
13/11/202422:00PRNUSEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
12/11/202422:56PRNCAEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Period
Draw mode


Loading Follow Feed...

Latest Eupraxia Pharmaceuticals Inc Articles

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 65%* for Gold Trader

1 year 40%, 2 years 50% and *3 years 65%

*Across 3 years £3655.44 only £1279.40